A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
A phase 2 trial of Brentuximab vedotin, Cyclophosphamide, Doxorubicin and Prednisone in non-Hodgkin lymphoma, run by Takeda, active and no longer recruiting.
Overview
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) is a phase 2 interventional study registered as NCT05673785 by Takeda, with 52 participants enrolled, started 2023-02-10 and due to reach its primary completion in 2025-04-27. Interventions recorded: Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialTucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Shares Prednisone, Cyclophosphamide, Doxorubicin, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Shares Prednisone, Cyclophosphamide, Doxorubicin, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Shares Takeda, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Shares Brentuximab vedotin, Takeda, Doxorubicin and the tag pipeline.
- TrialA Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Shares Prednisone, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialA Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Shares Prednisone, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Shares Prednisone, Doxorubicin, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialSafety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Shares Prednisone, Cyclophosphamide, Doxorubicin and the tag pipeline.